

ANZMTG Scientific Research and Annual General Meeting

Monday 10th December 2012 from 10:00am to 4:00pm

Melanoma Institute Australia, The Poche Centre,

40 Rocklands Road, North Sydney, NSW, Australia

Annual Scientific Research Meeting Agenda

Full and Associate ANZMTG members are invited to attend. Refreshments provided from 10am.

Speaker

Time

1. Introduction and Welcome

10:30am

ANZMTG Chairman Professor John Thompson & 2012 ASM Convenor Professor Bryan Burmeister

2. Closed and Current ANZMTG Clinical Trials; Session Chair: Bryan Burmeister

10:30am-11am

i. ANZMTG 01.02 A randomised clinical trial of surgery versus surgery plus adjuvant radiotherapy for regional control in patients with completely resected macroscopic nodal metastatic melanoma

Michael
Henderson

5 minutes each
speaker

ii. ANZMTG 01.07 Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - A randomised phase III trial & Overview of Current Sub Studies

Angela Hong

iii. ANZMTG 01.09 A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck

Matthew Foote

iv. ANZMTG 02.09 Vitamin D following primary treatment of melanoma at high risk of recurrence: A pilot placebo controlled randomised phase II trial

Robyn Saw

v. ANZMTG 01.11 Phase I Study of Safety and Immune Effects of an Escalating Dose of Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T Cells in Patients with Metastatic Melanoma

Michael Brown

vi. EORTC QOL Melanoma Module (refer to Trial Summary)

3. ANZMTG Approved Trials In Development; Session Chair: Bryan Burmeister

11am-11:30am

vii. A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails

Pascale Guitera

15 minutes each
speaker [5 min
presentation & 10
min discussion]

viii. Radiotherapy followed by selective nodal dissection for high volume regional melanoma

Matthew Foote

4. Proposed Studies and New Research Proposals (Part 1); Session Chair: Bryan Burmeister

11:30am-12:30pm

ix. Phase 1/2 trial examining safety and biological effects of combining Ipilimumab and palliative radiotherapy in patients with metastatic melanoma.

Kathy Pope

15 minutes
each speaker

x. An open-label, single-arm, phase I/II, multicenter study to evaluate the safety and efficacy of the combination of dabrafenib (GSK2118436), trametinib (GSK1120212) and palliative radiotherapy for the treatment of extra-cranial metastases in patients with BRAF mutant metastatic melanoma

Tim Wang

[5 min
presentation & 10
min discussion]

xi. EORTC 18081 - Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bNOMO: a randomized phase III trial

Peter Hersey

Lunch; Full ANZMTG members invited to attend the ANZMTG AGM

12:30pm-
1:30pm

Afternoon Sessions	Speaker	Time
5. Proposed Studies and New Research Proposals – (Part 2); <i>Session Chair: Bryan Burmeister</i>		
xii. Inguinal or Ilio-inguinal Lymph Node Dissection for patients with metastatic melanoma to groin lymph nodes and no evidence of pelvic disease on PET / CT Scan – A randomised phase III trial	<i>Andrew Spillane</i>	15 minutes each speaker [5 min presentation & 10 min discussion]
o Lymphoedema prevention following lymph node dissection for metastatic melanoma	<i>Chris Allan (videolink)</i>	
xiii. Melanoma Excision Margins Trial	<i>Marc Moncrieff (videolink)</i>	
<i>Discussion of New Proposals</i>	<i>Bryan Burmeister</i>	2:15-2:30pm
6. Melanoma Research Presentations; <i>Session Chair: Bryan Burmeister</i>		
<i>D-Day for Melanoma? Clinical trials with targeted drugs and immunostimulants</i>	<i>Rick Kefford</i>	2:30-3:00pm
<i>6th World Meeting of Melanoma Skin Cancer Centres 2012 Update</i>	<i>John Thompson</i>	3:00-3:10pm
<i>What QOL instruments should be used for melanoma trials and why?</i>	<i>Madeleine King</i>	3:10–3:30pm
<i>Australian Melanoma Consumer Alliance – National consumer engagement initiatives</i>	<i>Campbell Rose</i>	3:30 -3:45pm
7. Concluding Remarks; <i>Session Chair: Bryan Burmeister</i>		
Meeting close at 4:00pm		

ANZMTG Annual General Meeting 2012

Full ANZMTG members are welcome to attend the AGM, commences at 12:40pm

Agenda	Speaker	Attachments
1 Greetings and Apologies	<i>Chairman, Prof John Thompson</i>	
2 Review and Approve Minutes of Previous Meeting	<i>John Thompson</i>	2011 AGM Minutes (1)
3 Chairman's report	<i>John Thompson</i>	Chairman's report (2)
4 Finance report	<i>Libby Paton</i>	Financial statement 11/12 (3)
5 Operations report	<i>Libby Paton</i>	ANZMTG Clinical Trials Summary (4) ANZMTG Membership & Activities (5) ANZMTG Publications Summary (6)
6 Executive Committee Terms of Reference and Nomination Process	<i>John Thompson</i>	
7 Other business	All	
8 Meeting Close at 12:50pm		